3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
Illumina (NASDAQ: ILMN) has been -- and still is -- a leader in one of the most important scientific advances in human history. The company's technology helped usher in widespread use of gene sequencing, which has led to greater understanding of many genetic diseases. As a result, Illumina has been a fantastic growth stock, with its share price soaring nearly 900% since the company's IPO in 2000.
But another company has stood on the shoulders of Illumina. Exact Sciences (NASDAQ: EXAS) markets the Cologuard DNA test for colorectal cancer. Without the progress made possible by Illumina, Exact Sciences might not even exist. However, despite Illumina's impressive past and great prospects for the future, Exact Sciences is the better growth stock. Here are three reasons why.
Image source: Getty Images.
Source: Fool.com
Illumina Inc. Stock
With 33 Buy predictions and 4 Sell predictions Illumina Inc. is one of the favorites of our community.
With a target price of 161 € there is a positive potential of 35.39% for Illumina Inc. compared to the current price of 118.92 €.
